Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Harvard Business School
Express Scripts
Dow

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JUXTAPID

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for JUXTAPID

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01915771 Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects Completed Aegerion Pharmaceuticals, Inc. Phase 1 2013-08-01 Objectives: To evaluate the intra-subject variability of the pharmacokinetics (PK) of single oral capsule doses of 20 mg lomitapide.
NCT02044419 A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled Completed Aegerion Pharmaceuticals, Inc. Phase 1 2013-10-01 To compare the relative bioavailability of lomitapide when administered by sprinkling the contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral intact capsule dose of 20 mg lomitapide in healthy subjects.
NCT02080455 Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects. Completed Aegerion Pharmaceuticals, Inc. Phase 1 2014-02-01 The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.
NCT02080468 Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects Completed Aegerion Pharmaceuticals, Inc. Phase 1 2014-02-01 The primary objective of this study is to assess the effect of ethinyl estradiol (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and 2 primary metabolites, M1 and M3.
NCT02135705 LOWER: Lomitapide Observational Worldwide Evaluation Registry Enrolling by invitation Aegerion Pharmaceuticals, Inc. N/A 2014-03-01 This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for JUXTAPID

Condition Name

Condition Name for JUXTAPID
Intervention Trials
Healthy 2
Homozygous Familial Hypercholesterolemia 1
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide 1
Intra-subject Variability of Pharmacokinetics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for JUXTAPID
Intervention Trials
Hypercholesterolemia 1
Hyperlipoproteinemia Type II 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for JUXTAPID

Trials by Country

Trials by Country for JUXTAPID
Location Trials
United States 3
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for JUXTAPID
Location Trials
Texas 2
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for JUXTAPID

Clinical Trial Phase

Clinical Trial Phase for JUXTAPID
Clinical Trial Phase Trials
Phase 1 4
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for JUXTAPID
Clinical Trial Phase Trials
Completed 4
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for JUXTAPID

Sponsor Name

Sponsor Name for JUXTAPID
Sponsor Trials
Aegerion Pharmaceuticals, Inc. 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for JUXTAPID
Sponsor Trials
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Medtronic
Dow
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.